Healthcare Industry News: S.A.
News Release - June 20, 2014
ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing
MIAMI LAKES, Fla., June 20, 2014 -- (Healthcare Sales & Marketing Network) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, haS.A.pointed William Creech as Vice President SaleS.A.d Marketing.Mr. Creech has over 20 years of successful experience in the diagnostics industry. His last assignment was with Vermillion Inc., a diagnostics company, as Vice President SaleS.A.d Marketing, leading the commercialization of a novel test for ovarian cancer. Prior to that, Mr. Creech worked in various capacities of increasing responsibilities with Abbott Laboratories Diagnostics Division, Siemens Healthcare and Thermo Fisher Scientific, where he was VP SaleS.A.d Marketing, Capitol Vial subsidiary.
Mohan Gopalkrishnan, Chief Executive Officer of ERBA Diagnostics, said, "Mr. Creech iS.A.key addition to our management team and will focus on building a strong saleS.A.d marketing organization to deliver our growth objectives. We expect that his rich experience and knowledge of the diagnostics industry will add to our strategic focus in product development and future acquisitions."
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, iS.A.fully integrated in vitro diagnostics company that develops, manufactureS.A.d distributes in the United S.A.eS.A.d internationally, proprietary diagnostic reagents, test kitS.A.d instrumentation, primarily for autoimmune and infectious diS.A.es, clinical chemistry, hematology and diabetes through its six subsidiaries -- Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).
Safe Harbor S.A.ement
Except for the historical matters contained herein, S.A.ements in this press release are forward-looking and are made purS.A.t to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. InvestorS.A.e cautioned that forward-looking S.A.ements involve riskS.A.d uncertainties that may affect the businesS.A.d prospects of ERBA Diagnostics, Inc., including, without limitation: the riskS.A.d uncertaintieS.A.sociated with ERBA Diagnostics' business strategies, including, without limitation, the risk Mr. Creech'S.A.pointment may not build a strong saleS.A.d marketing organization, achieve growth objectives or increase focus in product development and future acquisitions, or otherwise; the risk Mr. Creech'S.A.pointment may not have a positive impact on ERBA Diagnostics' business strategieS.A.d may not be successful in ERBA DiagnosticS.A.hieving improved sales or operating results; and other riskS.A.d uncertainties that may cause results to differ materially from those set forth in the forward-looking S.A.ements. In addition to the riskS.A.d uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other riskS.A.d uncertainties discussed in ERBA Diagnostics' filings with the SecuritieS.A.d Exchange Commission, including, without limitation, the riskS.A.d uncertainties discussed under the heading "Risk Factors" in such filings.
Source: ERBA Diagnostics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!